nct_id: NCT05824975
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-04-24'
study_start_date: '2023-05-30'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: doxorubicin'
  - drug_name: 'Drug: paclitaxel'
  - drug_name: 'Drug: trastuzumab deruxtecan (T-DXd)'
  - drug_name: 'Drug: eribulin'
  - drug_name: 'Drug: GI-102 subcutaneous (SC)'
  - drug_name: 'Drug: GI-102'
  - drug_name: 'Drug: bevacizumab'
  - drug_name: 'Drug: pembrolizumab'
long_title: An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study
  to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity
  of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and
  in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab
  Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
last_updated: '2024-11-25'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: GI Innovation, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 358
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- "* Males and females aged \u2265 18 years (or \u2265 19 years according to local\
  \ regulatory guidelines) at the time of screening."
- '* Has adequate organ and marrow function as defined in protocol.'
- '* Measurable disease as per RECIST v1.1.'
- '* ECOG performance status 0-1.'
- "* Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy,\
  \ other prior systemic anti-cancer therapy, or surgery must have resolved to Grade\
  \ \u22641, except alopecia and Grade 2 peripheral neuropathy."
- '* HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled
  HIV infection/disease as defined in protocol.'
- 'Exclude - Key Exclusion Criteria:'
- Exclude - * Has known active CNS metastases and/or carcinomatous meningitis.
- Exclude - * An active second malignancy.
- Exclude - * Has active or a known history of Hepatitis B or known active Hepatitis
  C virus infection.
- Exclude - * Has active tuberculosis or has a known history of active tuberculosis.
- Exclude - * Active or uncontrolled infections, or severe infection within 4 weeks
  before study treatment administration.
- Exclude - * History of chronic liver disease or evidence of hepatic cirrhosis, except
  patients with liver metastasis.
- Exclude - * Has an active autoimmune disease that has required systemic treatment
  in past 2 years.
- Exclude - * Previous immunotherapies related to mode of action of GI-102.
- Exclude - * Has a diagnosis of immunodeficiency or is receiving chronic systemic
  steroid therapy or any other form of immunosuppressive medications within 2 weeks
  prior to Cycle 1 Day 1.
- Exclude - * Administration of prior systemic anti-cancer therapy including investigational
  agents within 4 weeks prior to treatment.
- Exclude - * Radiotherapy within the last 2 weeks before start of study treatment
  administration, with exception of limited field palliative radiotherapy.
- Exclude - * Administration of a live, attenuated vaccine within 4 weeks before Cycle
  1 Day 1.
- Exclude - * Known hypersensitivity to any of the components of the drug products
  and/or excipients of GI-102.
- Exclude - Other protocol defined inclusion exclusion criteria may apply
short_title: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As
  a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab
  or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: GI Innovation, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,
  and therapeutic activity of GI-102 as a single agent and in combination with conventional
  anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of
  advanced and/or metastatic solid tumors.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: GI-102
      arm_internal_id: 0
      arm_description: 'Dose escalation: GI-102 intravenous (IV), multiple ascending
        doses Dose optimization: GI-102 intravenous (IV), sRP2D Dose optimization:
        GI-102 intravenous (IV), sRP2D-1 (or sRP2D+1)'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: GI-102'
        level_internal_id: 0
        level_suspended: N
    - arm_code: GI-102 subcutaneous (SC)
      arm_internal_id: 1
      arm_description: 'Dose escalation: GI-102 subcutaneous (SC), multiple ascending
        doses Dose expansion: GI-102 subcutaneous (SC), sRP2D'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: GI-102 subcutaneous (SC)'
        level_internal_id: 0
        level_suspended: N
    - arm_code: GI-102 + doxorubicin
      arm_internal_id: 2
      arm_description: GI-102 + doxorubicin
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: doxorubicin'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: GI-102'
        level_internal_id: 1
        level_suspended: N
    - arm_code: GI-102 + paclitaxel + bevacizumab
      arm_internal_id: 3
      arm_description: GI-102 + paclitaxel + bevacizumab
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: paclitaxel'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: bevacizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: GI-102'
        level_internal_id: 2
        level_suspended: N
    - arm_code: GI-102 + eribulin
      arm_internal_id: 4
      arm_description: GI-102 + eribulin
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: eribulin'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: GI-102'
        level_internal_id: 1
        level_suspended: N
    - arm_code: GI-102 + trastuzumab deruxtecan (T-DXd)
      arm_internal_id: 5
      arm_description: GI-102 + trastuzumab deruxtecan (T-DXd)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: trastuzumab deruxtecan (T-DXd)'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: GI-102'
        level_internal_id: 1
        level_suspended: N
    - arm_code: GI-102 + pembrolizumab
      arm_internal_id: 6
      arm_description: GI-102 + pembrolizumab
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: pembrolizumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: GI-102'
        level_internal_id: 1
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Metastatic
        oncotree_primary_diagnosis: _SOLID_
